Calcium Channel Blockers and Raynaud's Disease
Authors: MICHEL VAYSSAIRAT
Journal: Annals of Internal Medicine (1981)

Letters and Corrections1 August 1981Calcium Channel Blockers and Raynaud's DiseaseMICHEL VAYSSAIRAT, M.D., LOIC CAPRON, M.D., JEAN-NÖEL FIESSINGER, M.D., JEAN-FRANÇOIS MATHIEU, M.D., EDWARD HOUSSET, M.D.MICHEL VAYSSAIRAT, M.D., LOIC CAPRON, M.D., JEAN-NÖEL FIESSINGER, M.D., JEAN-FRANÇOIS MATHIEU, M.D., EDWARD HOUSSET, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-95-2-243_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The letter by Kahan and associates (1), prompts us to report the main findings of a study on the effects of another calcium channel blocking agent, Diltiazem, in Raynaud's disease. A detailed description of these results is in preparation.Twenty six patients with Raynaud's disease (19 men; seven women; mean age, 36 years; mean follow-up of disease, 7 years; reasonably excluding all cases of secondary Raynaud's phenomenon) were observed for two consecutive periods of 14 days. During the first period no treatment was given (baseline observation). During the second period, patients were randomly allocated to either placebo...Reference1. KAHANWEBERAMORSAPORTAHODARADEGEORGES ASBLMM. Nifedipine and Raynaud's phenomenon. Ann Intern Med. 1981;94:546. Letter. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Claire de Clinique Médicale et de Pathologie Vasculaire Hôpital Broussais 75674 Paris CEDEX 14 France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByRaynaud's phenomenon: Pathogenesis and managementSyndrome de Raynaud chez l'enfant. Étude de 23 casEVALUATION AND TREATMENT OF HYPERTENSIONComprehensive Management Of Raynaud'S SyndromeCold-Induced Skin DisordersRaynaud's phenomenon in the emergency departmentDiagnosis and treatment of vasospastic disorders12 Calcium channel blockersControlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenonRaynaud's phenomenon. An update.Double-Blind Placebo-Controlled Trial of Buflomedil in the Treatment of Raynaud's Phenomenon: Six-Month Follow-upKlinischer Einsatz der KalziumantagonistenCalcium-channel blockers and anaesthesiaPathogenesis and treatment of Raynaud's phenomenonUse and Comparative Efficacy in Hypertension and Supraventricular Arrhythmias. Minor IndicationsLe traitement médical du syndrome de RaynaudTemperature-dependent skin disordersCalcium channel antagonists part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indicationsClinical Use of Calcium Antagonists in Peripheral Circulatory DiseaseReferencesIndikationen für Calcium-AntagonistenCalcium Channel BlockersNew Drug Therapy in Peripheral Vascular DiseaseInhibiteurs calciques et anesthésieDifferential Effects of 1,4-Dihydropyridine Calcium Channel Blockers: Therapeutic ImplicationsCalcium Modulators: Future Agents, Future UsesNicardipine in the treatment of raynaud'sNicardipine in the Treatment of Raynaud's Phenomenon: A Randomized Double-Blind TrialNisoldipine in primary Raynaud's phenomenonEffects of Calcium Antagonists on α-Adrenoceptor Mediated Vasoconstrictions of the Canine Intermediate Auricular ArteryScleroderma and scleroderma-like disordersControlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenonPharmacological Treatment of Raynaud's Phenomenon with Special Reference to Calcium-Entry Blockers.Effects of Diltiazem on Occupational Raynaud's Syndrome (Vibration Disease)The peripheral vascular effects of diltiazem-dose-response characteristics.Some Extracardiac Effects of Diltiazem and Other Calcium Entry BlockersTreatment of Raynaud's phenomenon with calcium channel blockersRaynaud's phenomenon: Pathophysiologic features and treatment with calcium-channel blockersA randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.Promising Uses of Calcium-Channel Blocking AgentsDiltiazemTreatment of Digital Vasospastic Disease with the Calcium-Entry Blocker NifedipineClinical effect of diltiazem acid (Herbesser tablet) for Raynaud phenomenon. A double blind trial comparing with placebo.Possible treatment of pre-eclampsia with calcium channel blocking agentsNifedipine Treatment for Pulmonary Hypertension in a Patient with Systemic SclerosisLimb ischemia caused by small artery diseaseRaynaud's VasospasmNifedipine and a Diabetic UlcerROBERT J. LAZARUS, M.D., ALTUG ONOR, M.D., KHAN HAMEED, M.D.CLINICAL SIGNIFICANCE OF RESISTANT CORYNEBACTERIA GROUP JKEPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROMERaynaud's Disease and NifedipineE. HARRIS PIERCE, M.D., M.S., ROBERT DELLAVALLE, PHARM. D., JAMES WIELENGA, PHARM. D.Clinical applications of slow channel blocking compoundsCalcium antagonists: A new class of drugsCONTROLLED TRIAL OF NIFEDIPINE IN THE TREATMENT OF RAYNAUD'S PHENOMENONNifedipine in digital ulceration in sclerodermaDiltiazem and Raynaud's SyndromeMATOBA TSUNETAKA, M.D., MASAHIKO OGATA, M.D., HIROSHI KUWAHARA, M.D.Chapter 9. Antithrombotic Agents 1 August 1981Volume 95, Issue 2Page: 243-243KeywordsCalcium channel blockerCalcium channelsRaynaud syndrome Issue Published: 1 August 1981 PDF DownloadLoading ...